BOSTON, August 7, 2006 — NanoBio Corporation, a private biopharmaceutical company, has secured a $30 million private equity investment from Perseus, L.L.C. The funding, which will come in three tranches, will support NanoBio's expanding clinical pipeline. NanoBio has developed multiple topical anti-infective products and vaccine candidates derived from its patented NanoStat technology platform. The company is developing and commercializing a range of products based on a proprietary nanoemulsion technology originally developed at the University of Michigan Medical School. NanoBio's lead product candidates are treatments for cold sores and nail fungus and a mucosal vaccine for influenza.